Research programme: antimalarial implants - Titan Pharmaceuticals

Drug Profile

Research programme: antimalarial implants - Titan Pharmaceuticals

Alternative Names: Atovaquone implant; Doxycycline implant; Piperaquine implant; ProNeura™ antimalarial implants; ProNeura™ antimalarial implants - Titan; ProNeura™ atovaquone implant; ProNeura™ doxycycline implant; ProNeura™ piperaquine implant

Latest Information Update: 11 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Titan Pharmaceuticals
  • Class Antimalarials; Piperazines; Quinolines; Small molecules; Tetracyclines
  • Mechanism of Action Electron transport complex I inhibitors; Hemozoin inhibitors; Protein 30S ribosomal subunit inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Malaria

Most Recent Events

  • 06 Jul 2017 Titan Pharmaceuticals establishes CRADA with the Walter Reed Army Institute of Research and Southwest Research Institute for the development of ProNeura™ based implants in Malaria
  • 06 Jul 2017 Preclinical trials in Malaria in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top